Behaviour research and therapy · 2024
Efficacy and working mechanisms of a Go/No-Go task-based inhibition training in smoking: A randomized-controlled trial.
СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Motka Franziska, Wittekind Charlotte E, Ascone Leonie, Kühn Simone
Аннотация
OBJECTIVE: Deficits in inhibitory control contribute to smoking behavior. Inhibitory control training (ICT), which involves repeatedly inhibiting responses to general or substance-related stimuli, shows promise in reducing problematic substance use. This preregistered randomized-controlled trial is the first to investigate the efficacy of general and smoking-specific Go/No-Go task-based ICT on smoking behavior compared to control groups receiving no ICT. Three potential working mechanisms were examined: inhibitory enhancement, automatic stimulus-stop associations, and stimulus devaluation.
METHOD: Individuals who smoke (N = 122) were randomly assigned to complete 28 sessions of smoking-specific Go/No-Go, general Go/No-Go, Sham training, or to a Waitlist control condition. Clinical outcomes included daily cigarettes (primary outcome), carbon monoxide levels, tobacco dependence severity, and craving, assessed at post-intervention and 3-month follow-up.
RESULTS: Go/No-Go training resulted in a significantly greater reduction in tobacco dependence (β = -0.88, p = .004) and craving (β = -4.31, p = .012) post-intervention compared to both control groups. The greater reduction in craving remained significant when compared to the Sham training group only (β = -4.64, p = .026). No significant effects of group were observed on daily cigarette consumption (β = -1.97, p = .093) or carbon monoxide levels (β = 2.16, p = .818) post-intervention. At the 3-month follow-up, no significant effects of group emerged (all ps > .794). Smoking-specific Go/No-Go training did not outperform general Go/No-Go training (all ps > .075). No working mechanism for clinical outcome improvements was identified.
CONCLUSIONS: Preliminary evidence suggests that (smoking-specific) GNG training reduces tobacco dependence severity and craving post-intervention in individuals who smoke compared to non-ICT-based control conditions. Its efficacy as an add-on in smoking cessation needs to be investigated.
CLINICAL TRIAL REGISTRATION NUMBER: DRKS00014652.
METHOD: Individuals who smoke (N = 122) were randomly assigned to complete 28 sessions of smoking-specific Go/No-Go, general Go/No-Go, Sham training, or to a Waitlist control condition. Clinical outcomes included daily cigarettes (primary outcome), carbon monoxide levels, tobacco dependence severity, and craving, assessed at post-intervention and 3-month follow-up.
RESULTS: Go/No-Go training resulted in a significantly greater reduction in tobacco dependence (β = -0.88, p = .004) and craving (β = -4.31, p = .012) post-intervention compared to both control groups. The greater reduction in craving remained significant when compared to the Sham training group only (β = -4.64, p = .026). No significant effects of group were observed on daily cigarette consumption (β = -1.97, p = .093) or carbon monoxide levels (β = 2.16, p = .818) post-intervention. At the 3-month follow-up, no significant effects of group emerged (all ps > .794). Smoking-specific Go/No-Go training did not outperform general Go/No-Go training (all ps > .075). No working mechanism for clinical outcome improvements was identified.
CONCLUSIONS: Preliminary evidence suggests that (smoking-specific) GNG training reduces tobacco dependence severity and craving post-intervention in individuals who smoke compared to non-ICT-based control conditions. Its efficacy as an add-on in smoking cessation needs to be investigated.
CLINICAL TRIAL REGISTRATION NUMBER: DRKS00014652.